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previously thought: it is an important early 
biomarker in its own right. Now we will have 
to work harder: oliguria should be seen in the 
context of early and frequent measurement 
of known and upcoming biomarkers, and in 
relationship with the overall fl uid status of 
the patient. Enriched with that information, 
we must continue to devise novel strategies 
of early AKI management. 
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 Hematologic malignancies have long been 
linked with glomerular disorders, and the 
list of such associations is continually 
expanding ( Table 1 ), although the patho-
genic mechanisms underlying a number of 
these glomerular lesions remain unclear. 
Th e most well-recognized and well-estab-
lished associations between hematologic 
and glomerular disorders are those involv-
ing plasma-cell dyscrasias, in which the 
monoclonal paraprotein or a product 
derived from it is deposited in the glomer-
uli, resulting initially in proteinuria and 
later, with increasing deposition of the 
abnormal protein, in renal insuffi  ciency. 
The spectrum of monoclonal immuno-
globulin deposition disease (MIDD) has 
been reviewed, 1 and our understanding of 
the amyloido genic properties of certain 
light chains is increasing. 2 Of course, renal 
involvement in MIDD and AL amyloidosis 
is not limited to glomeruli, although their 
progression often involves worsening 
glomerular pathology. Immunotactoid 
glomerulopathy, a rare lesion characterized 
by deposits within glomerular capillaries 
and mesangial areas that have a microtubu-
lar structure by electron microscopy, has 
emerged as another form of glomerular 
deposition disease associated with hemato-
logic neoplasms. Glomerular deposits in 
immunotactoid glomerulopathy are fre-
quently monoclonal, although the under-
lying hematologic disease is most oft en a 
low-grade B-cell neoplasm rather than a 
plasma-cell dyscrasia. This frequent 
association with B-cell neoplasms and the 
presence of monoclonal IgG within the 
glomerular deposits represent features that 
distinguish immunotactoid glomerulopa-
thy from the morphologically related lesion 
of fi brillary glomerulonephritis, which is 
only rarely associated with hematologic 
neoplasms and typically has polyclonal 
glomerular IgG deposits. 3 
 Deposition of monoclonal proteins in the 
context of hematologic neoplasms may also 
produce a pattern of proliferative glomeru-
lonephritis (GN) that must be distinguished 
from type I membranoproliferative GN 
(MPGN) and other forms of proliferative 
GN ( Table 1 ). Cryoglobulinemic GN due 
to monoclonal, type I cryoglobulins is rare 
but has a morphologic pattern similar to 
that of the more commonly seen cryoglob-
ulinemic GN with type III cryoglobulins, 
usually related to hepatitis C. 4 Unlike type 
I cryoglobulinemic GN, the more recently 
described proliferative GN with mono-
clonal IgG deposits is only infrequently 
associated with an underlying lymphoma 
or leukemia and is oft en seen in the absence 
of a detectable serum or urine paraprotein. 
However, this latter form of GN typically 
has an MPGN-type pattern, albeit without 
the intracapillary pseudothrombi and 
annular substructure of the deposits oft en 
seen in cryoglobulinemic GN. 5 It should 
also be remembered that intermediate- and 
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high-grade B-cell lymphomas that do not 
secrete monoclonal proteins may nonethe-
less produce a pattern of glomerular injury 
resembling a proliferative GN. One in par-
ticular, intravascular large B-cell lymphoma 
(IVLBCL), is characterized by neoplastic 
cells with an affi  nity for growth within small 
vessels and can cause end-organ damage in 
the kidney by obstructing glomerular and 
peritubular capillaries. 6 Patients with IVL-
BCL involving glomeruli usually present 
with renal failure and proteinuria that is 
nephrotic-range in approximately 50 % . 
Local release of permeability-enhancing 
cytokines by neoplastic lymphocytes 
or injured endothelial cells has been sug-
gested as a mechanism for podocyte injury 
and proteinuria. 6 
 Minimal-change nephropathy has been 
reported with various malignancies, 
including lymphoid neoplasms, but is 
most strongly related to Hodgkin ’ s lym-
phoma (HL). 7 Th e exact pathogenesis of 
HL-related minimal-change nephropathy 
is not known, although it has been sug-
gested that an unidentified cytokine /
 permeability factor released by neoplastic 
cells is the cause of podocyte injury. 8 Th e 
fact that the nephrotic syndrome is fre-
quently steroid-resistant, resolving only 
when the tumor is adequately treated, 
strengthens the argument that tumor cells 
play a role in its pathogenesis. 7,8 
 Myeloproliferative neoplasm (MPN)-
related glomerulopathy is the most 
recently described form of glomerular 
injury due to hematopoietic disorders and 
is the first such entity associated with 
myeloid neoplasms. In the study by 
Said  et al. 9 (this issue), MPN-related 
glomerulopathy developed with a variety 
of MPNs, but primary myelofi brosis was 
by far the most common. Primary mye-
lofi brosis is defi ned as a proliferation of 
predominantly megakaryocytes and gran-
ulocytes within the bone marrow that 
eventually results in deposition of fi brous 
tissue and extramedullary hemato poiesis. 
Th e histologic features of MPN-related 
glomerulopathy include mesangial scle-
rosis and hypercellularity, segmental scle-
rosis, and intracapillary hematopoietic 
cells. Additionally, segmental subendo-
thelial electron-lucent widening with 
glomerular basement membrane double 
contours is observed ultrastructurally in 
some cases, mimicking a chronic throm-
botic microangiopathy. In the bone mar-
row,  production of growth factors 
including platelet-derived growth factor 
and transforming growth factor-  by 
megakaryocytes leads to myelofi brosis. 10 
Said  et al. 9 propose that thrombocytosis 
 Table 1  |  Patterns of glomerular involvement in hematopoietic neoplasms 
 Glomerular disease type  Most frequent association(s)  Clinical features  Pathological features 
 Matrix / abnormal protein accumulation 
 AL amyloid  Monoclonal paraprotein; mul-
tiple myeloma 
 Proteinuria; renal 
insuffi  ciency 
 Congo red-positive acellular deposits; randomly 
oriented fi brils (7 – 10  nm diameter) 
 Monoclonal immunoglobulin 
deposition disease (light 
chain, heavy chain, or both) 
 Monoclonal paraprotein; mul-
tiple myeloma 
 Proteinuria; renal 
insuffi  ciency 
 Deposits of monoclonal paraprotein (fi nely 
granular by EM) in TBMs, GBMs, mesangium; 
nodular glomerulosclerosis in  ~ 60 % 
 Myeloproliferative neoplasm-
related glomerulopathy 
 Myeloproliferative neoplasms, 
most often primary 
myelofi brosis 
 Proteinuria, usually 
nephrotic-range; renal 
insuffi  ciency 
 Mesangial sclerosis with variable hypercellularity; 
often changes of chronic TMA 
 Immunotactoid 
glomerulopathy 
 Low-grade B-cell lymphomas, 
particularly CLL 
 Proteinuria, usually 
nephrotic-range; often 
nephrotic syndrome 
 Often resembles membranous, may be lobular; 
deposits often contain monoclonal IgG; 
subepi-, sub endothelial and mesangial 
microtubular deposits by EM 
 Waldenstr ö m’s  Waldenstr ö m’s 
macroglobulinemia 
 Usually mild proteinuria  Large subendothelial deposits / pseudothrombi; 
proliferative changes typically mild or absent 
    
 Proliferative GN / hypercellular glomeruli 
 Proliferative GN with 
monoclonal IgG deposits 
 Monoclonal paraprotein 
in some but not all cases; 
myeloma / lymphoma 
uncommon 
 Nephrotic-range proteinuria; 
microhematuria; renal 
insuffi  ciency 
 MPGN or endocapillary proliferative GN; 
subendothelial and mesangial, with or 
without subepithelial, deposits 
 Cryoglobulinemic GN type I  Monoclonal IgG cryoglobulin; 
various leukemias / lymphomas; 
myeloma uncommon 
 Proteinuria, often nephrotic-
range; microhematuria; 
renal insuffi  ciency 
 MPGN pattern with pseudothrombi containing 
the cryoglobulin; deposits with tubular / annular 
substructure 
 Intraglomerular (intracapil-
lary) lymphoma / leukemia 
 Large B-cell lymphomas /
 leukemias 
 Proteinuria; microhematuria; 
renal insuffi  ciency 
 Malignant cells within glomerular capillaries; 
no immune deposits by IF / EM 
    
 Podocytopathy    
 Minimal-change 
nephropathy 
 Hodgkin’s lymphoma  Nephrotic syndrome, 
often steroid-resistant 
 Histologically unremarkable glomeruli; no 
immune deposits; foot process eff acement by EM 
 Abbreviations: CLL, chronic lymphocytic leukemia; EM, electron microscopy; IF, immunofl uorescence; GBM, glomerular basement membrane; GN, glomerulonephritis; MPGN, 
membranoproliferative GN; TBM, tubular basement membrane; TMA, thrombotic microangiopathy. 
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and intracapillary platelet / megakaryocyte 
aggregation lead to elevation of these fac-
tors systemically and within glomeruli. 
Platelet-derived growth factor stimulates 
mesangial-cell proliferation, mesangial 
matrix production, and podocyte apop-
tosis, while transforming growth factor-  
leads to mesangial-cell synthesis of col-
lagen and fi bronectin. 11,12 A combination 
of these eff ects probably gives rise to the 
glomerular lesion. Furthermore, aggrega-
tion of circulating hematopoietic cells 
within glomerular capillaries could poten-
tially result in endothelial injury and mor-
phologic changes resembling chronic 
thrombotic microangiopathy. 
 In the study by Said  et al. , 9 the clini-
cal manifestations of MPN-related 
glome rulopathy, namely proteinuria of 
more than 3 g / d with chronic renal 
insufficiency, tended to become mani-
fest late in the course of the myelopro-
liferative  disease (the mean time from 
diagnosis of MPN to renal biopsy was 
7.2 years).  Biopsies from 5 of 11 patients 
had more than 50 % globally sclerotic 
glomeruli, and four of these biopsies 
had moderate or severe tubulointersti-
tial scarring. Only one patient had fewer 
than 20 % of glomeruli showing global 
or segmental sclerosis. 
 Unlike several of the other glomeru-
lopathies listed in  Table 1 , the prognosis 
of MPN-related glomerulopathy was 
guarded even with corticosteroid therapy, 
renin – angiotensin system blockade, or 
treatment of the underlying neoplasm. 9 
However, this is based on experience with 
only 11 patients, the majority of whom 
had considerable chronic renal disease at 
the time of diagnosis. Whether earlier 
recognition of MPN-related glomeru-
lopathy might have resulted in better renal 
outcomes is unclear, yet evidence from 
other glomerular diseases, both primary 
and secondary, suggests that this is not 
unreasonable. Two prognostic features are 
common to a wide variety of glomerular 
diseases. First, the most important mor-
phologic predictors of renal outcome at 
the time of renal biopsy are the extent of 
glomerular sclerosis and of tubular 
atrophy / interstitial fi brosis. 5,13 Second, in 
diseases ranging from focal segmental 
glomerulosclerosis to lupus nephritis, a 
key predictor of long-term renal progno-
sis is the response to initial therapy. 14,15 
Th is raises the issues of whether and how 
frequently we should be screening patients 
with hematologic neoplasms for urinary 
abnormalities, most notably proteinuria, 
which is a feature of all of the lesions listed 
in  Table 1 , and at what point detection of 
proteinuria should be an indication to 
perform a renal biopsy. It can be argued, 
in the case of certain neoplasms, including 
MPN, that performance of a renal biopsy 
in response to detection of mild, new-
onset proteinuria is not indicated without 
evidence from a controlled clinical trial 
that therapy improves the renal outcome, 
and clearly there is a need for such trials in 
MPN-related glomerulopathy and other 
glomerular diseases listed in  Table 1 , such 
as proliferative GN with monoclonal IgG 
deposits. It is also important that anti-
neoplastic treatment be ruled out as 
the cause of the urinary abnormalities, as 
some antineoplastic drugs are well docu-
mented to cause renal and, in some 
instances, glomerular injury. Still, a more 
aggressive approach to urinary screening 
and renal biopsy would at minimum give 
us a better idea of the frequency and time 
course of renal disease in MPN and might 
also provide useful information regarding 
the feasibility of a controlled clinical trial 
for treatment of MPN-related glomerulo-
pathy, and which potential therapies 
would best be included in such a trial. 
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